Dynacure develops new treatments for patients suffering from serious orphan disorders. The first drug discovery program of Dynacure focuses on Centronuclear Myo...
| Website | http://www.dynacure.fr |
| Revenue | $7.4 million |
| Employees | 6 (0 on RocketReach) |
| Industry | Biotechnology, Pharmaceuticals, Healthcare |
| Keywords | Orphan Drug Development, Rare Disease Therapies, New Therapies, Clinical Trials, Pharmaceutical Research, Biotechnology, Genetic Disorders, Medical Research, Patient Care, Health Solutions, Disease Treatment, Drug Development, Healthcare |
| Competitors | Amgen, Takeda, Vertex Pharmaceuticals, BioMarin Pharmaceutical Inc., アステラス製薬（株）, Sobi - Swedish Orphan Biovitrum AB (publ), Genzyme Europe B.V., bluebird bio, MorphoSys, Sarepta Therapeutics, Inc. +44 more (view full list) |
Looking for a particular Dynacure employee's phone or email?
Dynacure Questions
The Dynacure annual revenue was $7.4 million in 2026.
Dynacure is based in Strasbourg, Grand-Est.
G2Crowd Trusted
300K+
Plugin Users
